NCT05258279 2024-08-28Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR MutationsJuntendo UniversityPhase 2 Active not recruiting30 enrolled
NCT05849246 2024-08-20The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)Innovent Biologics (Suzhou) Co. Ltd.Phase 2 Terminated4 enrolled